A Study of Risperidone Monotherapy in Bipolar Anxiety

NCT ID: NCT00167479

Last Updated: 2006-09-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-09-30
• Study Completion Date: 2006-09-30

Brief Summary

The specific aim of this study is to evaluate the efficacy, tolerability, and safety of risperidone monotherapy in the treatment of ambulatory bipolar disorder with comorbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.

Detailed Description

This is a randomized, double-blind, placebo controlled, parallel-group, 8-week trial of risperidone monotherapy in outpatient subjects with a lifetime bipolar I, II, or NOS disorder, a lifetime panic or generalized anxiety disorder, and current at least moderately severe anxiety symptoms. Approximately 90 subjects will be enrolled to obtain 60 subjects who complete the 8-week trial. Subjects will be randomized to risperidone or placebo in a 1:1 ratio. No concomitant psychotropic medication will be allowed except for prn lorazepam during the first two weeks for the management of affective and anxiety symptoms, and prn zolpidem and zaleplon throughout the study for the management of insomnia. Throughout the study, psychiatric scales will be used to assess psychiatric symptoms and the presence of treatment-emergent adverse events will be monitored and recorded.

Conditions

Bipolar Disorder; Panic Disorder; Generalized Anxiety Disorder

Keywords

Bipolar Anxiety; Bipolar Disorder; Anxiety; Panic Disorder; Generalized Anxiety Disorder; GAD; Risperidone; Double-Blind; Placebo Controlled

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

risperidone (Risperdal)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects must be 18 years of age or older.

2. Subjects must have lifetime bipolar I, II, or NOS disorder as defined by DSM-IV criteria.

3. Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV criteria (except clause "does not occur exclusively during a mood disorder" of Criterion F for GAD) .

4. Subjects' bipolar symptoms must be no more than moderately severe, defined as a CGI-BP < 4.

5. Subjects' anxiety symptoms must be at least moderately severe, defined as a CGI-S > 4.

6. Subjects must not be receiving mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for > one week prior to baseline. Patients receiving fluoxetine or depot antipsychotics should be off these medications for > four weeks prior to baseline.

7. Subjects or their legally authorized representative must sign the Informed Consent Document after the nature of the trial has been fully explained.

8. If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable effective method(s) of contraception (e.g., hormonal methods, double barrier methods, intrauterine device) for at least one month prior to study entry and throughout the study.

Exclusion Criteria

1. Subjects who do not have lifetime bipolar disorder by DSM-IV-TR criteria.

2. Subjects who do not have lifetime panic disorder or generalized anxiety disorder by DSM-IV-TR criteria.

3. Subjects who are receiving treatment with an antimanic or mood stabilizing medication (lithium, valproate, carbamazepine, or an antipsychotic), and in the investigators' judgment, require ongoing treatment with that medication.

4. Subjects whose bipolar symptoms are presently more than moderately severe (CGI-BP > 5).

5. Subjects whose anxiety symptoms are presently less than moderately severe (CGI < 3).

6. Subjects with clinically significant suicidal or homicidal ideation.

7. Subjects with current psychotic symptoms.

8. Subjects with a current DSM-IV Axis I diagnosis of delirium, dementia, amnesia, or other cognitive disorders; a DSM-IV diagnosis of a substance dependence disorder within the past six months; a lifetime DSM-IV psychotic disorder (e.g., schizophrenia or schizoaffective disorder).

9. Subjects with serious general medical illnesses including hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, or hematologic disease as determined by the clinical judgment of the clinical investigator. Subjects with hypo- or hyperthyroidism unless stabilized on thyroid replacement > 3 months.

10. Subjects with a clinically significant abnormality in their prestudy physical exam, vital signs, EKG, or laboratory tests.

11. Subjects who are allergic to or who have demonstrated hypersensitivity to risperidone.

12. Women who are pregnant or nursing.

13. Subjects who have received an experimental drug or used an experimental device within 30 days.

14. Subjects who have a history of neuroleptic malignant syndrome.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen, LP

INDUSTRY

Sponsor Role: collaborator

University of South Florida

OTHER

Sponsor Role: lead

Principal Investigators

David V. Sheehan, MD, MBA

Role: PRINCIPAL_INVESTIGATOR

University of South Florida College of Medicine

Susan L. McElroy, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinatti, Department of Psychiatry

Trisha - Suppes, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Texas Southwestern Medical Center

Paul E. Keck, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinatti, Department of Psychiatry

Locations

University of South Florida Psychiatry Center

Tampa, Florida, United States

University of Cincinatti

Cincinnati, Ohio, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Countries

United States

Other Identifiers

RIS-BIP-408

Identifier Type: -

Identifier Source: secondary_id

101541d

Identifier Type: -

Identifier Source: org_study_id